Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in
patients with histologically proven chronic allograft nephropathy Indication: change in
immunosuppressive treatment of chronic allograft nephropathy (CAN)after renal transplantation
Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure/
metabolic parameters and structural vessel wall changes
Primary Target:effects of CNI withdrawal and MMF on renal function: stabilisation and/or
improvement Secondary Targets: Incidence of adverse events Evaluation of the calcineurin
inhibitor free MMF treatment effects on blood pressure, lipids, glucose metabolism and on
structural and functional vesselwallchanges Method:open prospective, randomized two-tailed,
monocentric study